Moderna Inc. (MRNA)

Moderna (MRNA) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.92. This compares to loss of $3.07 per share a year ago.

Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine...

Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of...

Moderna shares are down more than 30% this year, and around 75% over the past 12 months.

Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter...

In many ways, the pandemic is becoming a faded memory. With that, a major pandemic star -- biotech Moderna (MRNA -0.79%) -- also seems to be disappearing from the world's attention.

What should investors do during a stock-market correction? One great strategy is to go shopping.

The latest trading day saw Moderna (MRNA) settling at $27.19, representing a -0.75% change from its previous close.

When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.